Published in

Taylor and Francis Group, Expert Opinion on Therapeutic Targets, 12(11), p. 1571-1586, 2007

DOI: 10.1517/14728222.11.12.1571

Links

Tools

Export citation

Search in Google Scholar

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

Journal article published in 2007 by Maria E. Fratto, Antonio Russo, Viviana Bazan, Valentina Schiró, Valentina Agnese ORCID, Giuseppe Cicero, Bruno Vincenzi ORCID, Giuseppe Tonini ORCID, Daniele Santini
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.